Literature DB >> 22201890

Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies.

Beate Haeberle1, Dietrich von Schweinitz.   

Abstract

Treatment with neoadjuvant and adjuvant chemotherapy together with tumor resection changed treatment strategies in hepatoblastoma and led to prospective cooperative studies. The treatment strategies and results of three German liver tumor studies HB89, HB94 and HB99 are reviewed. Here we provide an overview of the treatment of this tumor in the years 1989 to 2008 in Germany. The treatment protocols, aim of studies and results are outlined. The overall-survival (OS), response to chemotherapy and toxicity are followed over this period of different treatment. The overall-survival improved over the last years with 75 % in HB89, 77 % in HB94 and 89 % HB99. Patients with potentially resectable tumors have a good prognosis although the treatment was reduced over the last years. Patients with non resectable tumors or lung metastases have also a better but still bad prognosis. The intensified treatment for these patients in Germany in the last years showed comparable results to international studies but no advantage.

Entities:  

Mesh:

Year:  2012        PMID: 22201890     DOI: 10.2741/395

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  7 in total

1.  Impact of microscopically margin-positive resection on survival in children with hepatoblastoma after hepatectomy: a retrospective cohort study.

Authors:  Xianghai Ren; Haibo Li; Mei Diao; Hang Xu; Long Li
Journal:  Int J Clin Oncol       Date:  2019-11-07       Impact factor: 3.402

2.  Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration.

Authors:  Rebecka L Meyers; Rudolf Maibach; Eiso Hiyama; Beate Häberle; Mark Krailo; Arun Rangaswami; Daniel C Aronson; Marcio H Malogolowkin; Giorgio Perilongo; Dietrich von Schweinitz; Marc Ansari; Dolores Lopez-Terrada; Yukichi Tanaka; Rita Alaggio; Ivo Leuschner; Tomoro Hishiki; Irene Schmid; Kenichiro Watanabe; Kenichi Yoshimura; Yurong Feng; Eugenia Rinaldi; Davide Saraceno; Marisa Derosa; Piotr Czauderna
Journal:  Lancet Oncol       Date:  2016-11-22       Impact factor: 41.316

3.  Truncated neurokinin-1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage.

Authors:  Agnès Garnier; Matthias Ilmer; Kristina Becker; Beate Häberle; Dietrich VON Schweinitz; Roland Kappler; Michael Berger
Journal:  Oncol Lett       Date:  2015-11-20       Impact factor: 2.967

4.  Tracking cellular and molecular changes in a species-specific manner during experimental tumor progression in vivo.

Authors:  Emilie Indersie; Katarzyna B Hooks; Caroline Capdevielle; Monique Fabre; Nathalie Dugot-Senant; Angélique Desplat; Sébastien Lepreux; Aksam Merched; Christophe F Grosset; Martin Hagedorn
Journal:  Oncotarget       Date:  2018-03-01

5.  Hepatoblastoma: Transplant Versus Resection Experience in a Latin American Transplant Center.

Authors:  Luis A Caicedo; Angie Sabogal; Oscar Serrano; Jorge I Villegas; Verónica Botero; María T Agudelo; Viviana Lotero; Diana Dávalos; Eliana Manzi; Ana M Aristizabal; Catalina Gomez; Gabriel J Echeverri
Journal:  Transplant Direct       Date:  2017-05-25

6.  CHIC Risk Stratification System for Predicting the Survival of Children With Hepatoblastoma: Data From Children With Hepatoblastoma in China.

Authors:  Junting Huang; Yang Hu; Hong Jiang; Yanjie Xu; Suying Lu; Feifei Sun; Jia Zhu; Juan Wang; Xiaofei Sun; Juncheng Liu; Zijun Zhen; Yizhuo Zhang
Journal:  Front Oncol       Date:  2020-11-18       Impact factor: 6.244

7.  Low expression of N-myc downstream-regulated gene 2 (NDRG2) correlates with poor prognosis in hepatoblastoma.

Authors:  Jan Gödeke; Elke Luxenburger; Franziska Trippel; Kristina Becker; Beate Häberle; Josef Müller-Höcker; Dietrich von Schweinitz; Roland Kappler
Journal:  Hepatol Int       Date:  2015-12-08       Impact factor: 6.047

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.